50
Participants
Start Date
January 1, 2024
Primary Completion Date
November 30, 2024
Study Completion Date
November 30, 2026
[68Ga] B7H3 Affibody-BCH
An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.
RECRUITING
Xiangxi Meng, Beijing
Peking University Cancer Hospital & Institute
OTHER